Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2490
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer ; volume:11 ; number:1 ; day:14 ; month:5 ; year:2011 ; pages:1-6 ; date:12.2011
BMC urology ; 11, Heft 1 (14.5.2011), 1-6, 12.2011
- Creator
-
Fujimoto, Naohiro
- Contributor
-
Kubo, Tatsuhiko
Shinsaka, Hideo
Matsumoto, Masahiro
Shimajiri, Shohei
Matsumoto, Tetsuro
SpringerLink (Online service)
- DOI
-
10.1186/1471-2490-11-7
- URN
-
urn:nbn:de:1111-2016071624398
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Fujimoto, Naohiro
- Kubo, Tatsuhiko
- Shinsaka, Hideo
- Matsumoto, Masahiro
- Shimajiri, Shohei
- Matsumoto, Tetsuro
- SpringerLink (Online service)
Other Objects (12)
PTP1B regulates lymphocytes responses androgen deprivation
Androgen deprivation modulates the inflammatory response induced by irradiation
Androgen receptor expression in the clinically localized prostate cancer
Androgen regulation of the androgen receptor coregulators
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice
PTP1B regulates lymphocytes responses androgen deprivation
Androgen deprivation modulates the inflammatory response induced by irradiation
Androgen receptor expression in the clinically localized prostate cancer
Androgen regulation of the androgen receptor coregulators
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer
Cardiovascular Impact of Androgen Deprivation Therapy: from Basic Biology to Clinical Practice
PTP1B regulates lymphocytes responses androgen deprivation
Androgen deprivation modulates the inflammatory response induced by irradiation
Androgen receptor expression in the clinically localized prostate cancer
Androgen regulation of the androgen receptor coregulators
Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
Adaptive phenotype drives resistance to androgen deprivation therapy in prostate cancer
Androgen deprivation in prostate cancer: benefits of home-based resistance training
Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
Long-term oncologic outcomes of radiotherapy combined with maximal androgen blockade for localized, high-risk prostate cancer
Survival and mortality of elderly men with localized prostate cancer managed with primary androgen deprivation therapy or by primary observation
Vascular responses to radiotherapy and androgen-deprivation therapy in experimental prostate cancer